Exome sequencing studies have recently demonstrated that papillary craniopharyngiomas (PCPs) and adamantinomatous craniopharyngiomas (ACPs) have distinct genetic origins, each primarily driven by mutually exclusive alterations: either BRAF (V600E), observed in 95% of PCPs, or CTNNB1, observed in 75%–96% of ACPs. How the presence of these molecular signatures, or their absence, correlates with clinical, radiographic, and outcome variables is unknown.
The pathology records for patients who underwent surgery for craniopharyngiomas between May 2000 and March 2015 at Weill Cornell Medical College were reviewed. Craniopharyngiomas were identified and classified as PCP or ACP. Patients were placed into 1 of 3 groups based on their genomic mutations: BRAF mutation only, CTNNB1 mutation only, and tumors with neither of these mutations detected (not detected [ND]). Demographic, radiological, and clinical variables were collected, and their correlation with each genomic group was tested.
Histology correlated strongly with mutation group. All BRAF tumors with mutations were PCPs, and all CTNNB1 with mutations and ND tumors were ACPs. Preoperative and postoperative clinical symptoms and radiographic features did not correlate with any mutation group. There was a statistically significant relationship (p = 0.0323) between the age group (pediatric vs adult) and the mutation groups. The ND group tumors were more likely to involve the sella (p = 0.0065).
The mutation signature in craniopharyngioma is highly predictive of histology. The subgroup of tumors in which these 2 mutations are not detected is more likely to occur in children, be located in the sella, and be of ACP histology.
ABBREVIATIONSACP = adamantinomatous craniopharyngioma; DI = diabetes insipidus; GTR = gross-total resection; ND = not detected; PCP = papillary craniopharyngioma.
Correspondence Theodore H. Schwartz, Department of Neurosurgery, Weill Cornell Medical College, NewYork-Presbyterian Hospital, 525 East 68th St., Box #99, New York, NY 10065. email: firstname.lastname@example.org.
INCLUDE WHEN CITING Published online July 14, 2017; DOI: 10.3171/2017.1.JNS162232.
Disclosures Dr. Souweidane reports that he is a consultant for Aesculap.
BusleiRNoldeMHofmannBMeissnerSEyupogluIYSiebzehnrüblF: Common mutations of β-catenin in adamantinomatous craniopharyngiomas but not in other tumours originating from the sellar region. Acta Neuropathol109:589–5972005
FjalldalSHolmerHRylanderLElfvingMEkmanBOsterbergK: Hypothalamic involvement predicts cognitive performance and psychosocial health in long-term survivors of childhood craniopharyngioma. J Clin Endocrinol Metab98:3253–32622013
HölskenASillMMerkleJSchweizerLBuchfelderMFlitschJ: Adamantinomatous and papillary craniopharyngiomas are characterized by distinct epigenomic as well as mutational and transcriptomic profiles. Acta Neuropathol Commun4:202016
LarkinSJPredaVKaravitakiNGrossmanAAnsorgeO: BRAF V600E mutations are characteristic for papillary craniopharyngioma and may coexist with CTNNB1-mutated adamantinomatous craniopharyngioma. Acta Neuropathol127:927–9292014
LengLZGreenfieldJPSouweidaneMMAnandVKSchwartzTH: Endoscopic, endonasal resection of craniopharyngiomas: analysis of outcome including extent of resection, cerebrospinal fluid leak, return to preoperative productivity, and body mass index. Neurosurgery70:110–1242012
LoACHowardAFNicholASidhuKAbdulsatarFHasanH: Long-term outcomes and complications in patients with craniopharyngioma: the British Columbia Cancer Agency experience. Int J Radiat Oncol Biol Phys88:1011–10182014
MarucciGde BiaseDZoliMFaustini-FustiniMBacciAPasquiniE: Targeted BRAF and CTNNB1 next-generation sequencing allows proper classification of nonadenomatous lesions of the sellar region in samples with limiting amounts of lesional cells. Pituitary18:905–9112015
MusumeciGCastorinaSCastrogiovanniPLoretoCLeonardiRAielloFC: A journey through the pituitary gland: Development, structure and function, with emphasis on embryo-foetal and later development. Acta Histochem117:355–3662015
OlssonDSAnderssonEBryngelssonILNilssonAGJohannssonG: Excess mortality and morbidity in patients with craniopharyngioma, especially in patients with childhood onset: a population-based study in Sweden. J Clin Endocrinol Metab100:467–4742015
PereiraAMSchmidEMSchuttePJVoormolenJHBiermaszNRvan ThielSW: High prevalence of long-term cardiovascular, neurological and psychosocial morbidity after treatment for craniopharyngioma. Clin Endocrinol (Oxf)62:197–2042005